We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Marjean Kulp

Marjean Kulp OD

Distinguished Professor, College of Optometry, Ohio State University, Columbus, OH
Dr. Marjean Taylor Kulp received her Doctor of Optometry in 1991 from The Ohio State University. She concurrently completed a Master's Degree in Physiological Optics and a Fellowship in Binocular Vision/Pediatrics in 1993. She is currently a Distinguished Professor of Optometry and Vision Science at The Ohio State University College of Optometry.  Dr. Kulp served (with Dr. Paulette Schmidt) as a Co-Investigator for the NEI-funded Vision In Preschoolers Study, which was designed to evaluate the effectiveness of a preschool vision screening tests. She served as Co-investigator with Dr. Elise Ciner on the NEI-funded Vision in Preschoolers-Hyperopia In Preschoolers (VIP-HIP) study.  She served as Principal Investigator (PI) of The OSU Clinical Center and as a member of the Executive Committee for the NEI-funded Convergence Insufficiency Treatment Trial and CITT-Attention and Reading Trial. She serves as Co-Chair for the Pediatric Eye Disease Investigator Group (PEDIG) Hyperopia Treatment Study. She also serves as Investigator at The Ohio State University College of Optometry for the Amblyopia Treatment Studies (ATS).  She served as PI at The OSU College of Optometry for a multi-center, double-masked, placebo-controlled, parallel, safety and efficacy study of 2% Pirenzepine Ophthalmic Gel in children with myopia (PIR 205) and also for the COMET 2 (Correction of Myopia Evaluation Trial 2) study.